Derek Lowe's blog "In the Pipeline" reports on a story about massive problems in regulatory oversight of drug approval in China.  

A report in the Chinese newspaper Economic Information Daily says that the Chinese SFDA (State Food and Drug Administration) has been conducting a review of Chinese clinical trial practices, and after reviewing 1,622 trials has found that most of them are seriously flawed. And by “seriously flawed”, they mean “largely faked”. 

The report focuses on generics for use inside China, but the problems probably extend to drugs for the export market as well.